ASCO GI 2026

ASCO GI 2026: New data at ASCO GI show durable first-line responses with amivantamab in metastatic colorectal cancer

ASCO GI 2026: Zanidatamab and chemotherapy can slow cancer growth, extend survival in some people with gastroesophageal adenocarcinoma

ASCO GI 2026: GLP-1 receptor agonists (GLP-1s) may help reduce the risk of developing colorectal cancer

ASCO GI 2026: Long-term study suggests walking is key to managing cancer-related fatigue

ASCO GI 2026: ‘triple-punch’ combo therapy slows progressions of some metastatic colorectal cancers

ASCO GI 2026: Combining encorafenib and cetuximab with FOLFIRI may be effective first-line treatment for advanced CRC

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

DW-MRI reduces futile surgery in colorectal peritoneal metastases undergoing cytoreductive surgery

FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC

Toripalimab plus chemotherapy improves 3-year survival in resectable gastric/GEJ cancer

Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma

Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer